Century Therapeutics, Inc. Increase (Decrease) in Accounts Payable
Century Therapeutics, Inc. (IPSC) reported Increase (Decrease) in Accounts Payable of $48.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-12
- Century Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $1.67M.
- Century Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$1.63M, a 550.14% decline year-over-year.
- Century Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $2.16M, a 352.20% increase year-over-year.
- Century Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$591.00K.
- Century Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2025 was $1.56M.
- Century Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2024 was -$1.47M.
- Century Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2023 was -$2.36M.
- Century Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2022 was -$4.79M.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $48.00K 10-Q · filed 2026-08-12 | $2.21M derived: sum of 3 quarters · filed 2026-08-12 | $1.61M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$1.63M 10-Q · filed 2026-05-13 | $532.00K derived: sum of 2 quarters · filed 2026-05-13 | -$59.00K derived: sum of 3 quarters · filed 2026-05-13 | -$424.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $2.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.57M derived: sum of 2 quarters · filed 2026-03-12 | $1.20M derived: sum of 3 quarters · filed 2026-08-12 | $1.56M 10-K · filed 2026-03-12 |
| 2025-09-30 | -$591.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$956.00K derived: sum of 2 quarters · filed 2026-08-12 | -$595.00K 10-Q · filed 2025-11-13 | -$118.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$365.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$4.00K 10-Q · filed 2026-08-12 | $473.00K derived: sum of 3 quarters · filed 2026-08-12 | -$284.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $361.00K 10-Q · filed 2026-05-13 | $838.00K derived: sum of 2 quarters · filed 2026-05-13 | $81.00K derived: sum of 3 quarters · filed 2026-05-13 | -$1.80M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $477.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$280.00K derived: sum of 2 quarters · filed 2026-03-12 | -$2.16M derived: sum of 3 quarters · filed 2026-03-12 | -$1.47M 10-K · filed 2026-03-12 |
| 2024-09-30 | -$757.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$2.63M derived: sum of 2 quarters · filed 2025-11-13 | -$1.95M 10-Q · filed 2025-11-13 | -$4.83M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$1.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$1.19M 10-Q · filed 2025-08-14 | -$4.08M derived: sum of 3 quarters · filed 2025-08-14 | -$82.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $689.00K 10-Q · filed 2025-05-15 | -$2.20M derived: sum of 2 quarters · filed 2025-05-15 | $1.80M derived: sum of 3 quarters · filed 2025-05-15 | $1.28M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$2.89M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $1.11M derived: sum of 2 quarters · filed 2025-03-19 | $593.00K derived: sum of 3 quarters · filed 2025-03-19 | -$2.36M 10-K · filed 2025-03-19 |
| 2023-09-30 | $3.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $3.48M derived: sum of 2 quarters · filed 2024-11-05 | $526.00K 10-Q · filed 2024-11-05 | -$1.11M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | -$514.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$3.47M 10-Q · filed 2024-08-08 | -$5.10M derived: sum of 3 quarters · filed 2024-08-08 | -$4.39M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$2.95M 10-Q · filed 2024-05-09 | -$4.59M derived: sum of 2 quarters · filed 2024-05-09 | -$3.88M derived: sum of 3 quarters · filed 2024-05-09 | -$6.24M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$1.63M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$927.00K derived: sum of 2 quarters · filed 2024-03-14 | -$3.29M derived: sum of 3 quarters · filed 2024-03-14 | -$4.79M 10-K · filed 2024-03-14 |
| 2022-09-30 | $706.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$1.65M derived: sum of 2 quarters · filed 2023-11-09 | -$3.15M 10-Q · filed 2023-11-09 | -$863.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$2.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$3.86M 10-Q · filed 2023-08-09 | -$1.57M derived: sum of 3 quarters · filed 2023-08-09 | -$2.15M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$1.50M 10-Q · filed 2023-05-11 | $789.00K derived: sum of 2 quarters · filed 2023-05-11 | $211.00K derived: sum of 3 quarters · filed 2023-05-11 | $1.59M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $2.29M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $1.71M derived: sum of 2 quarters · filed 2023-03-16 | $3.09M derived: sum of 3 quarters · filed 2023-03-16 | -$1.85M 10-K · filed 2023-03-16 |
| 2021-09-30 | -$578.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $798.00K derived: sum of 2 quarters · filed 2022-11-10 | -$4.14M 10-Q · filed 2022-11-10 | -$4.48M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $1.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$3.56M 10-Q · filed 2022-08-11 | -$3.90M derived: sum of 3 quarters · filed 2022-08-11 | -$2.30M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$4.94M 10-Q · filed 2022-05-16 | -$5.28M derived: sum of 2 quarters · filed 2022-05-16 | -$3.67M derived: sum of 3 quarters · filed 2022-05-16 | |
| 2020-12-31 | -$340.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $1.26M derived: sum of 2 quarters · filed 2022-03-17 | $2.06M 10-K · filed 2022-03-17 | |
| 2020-09-30 | $1.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $2.40M 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $797.00K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |